GondolaBio · 1 day ago
VP Oligonucleotide Therapeutics
Palo Alto, CA
Full-time
Onsite
Director/Executive
$290K/yr - $340K/yr
12+ years expGondolaBio is a clinical-stage biopharmaceutical company focused on developing breakthrough therapeutics for genetic diseases. The VP of Oligonucleotide Therapeutics will lead programs in oligonucleotide drug discovery and development, driving them from target validation through development candidate nomination and IND submission.
BiotechnologyManufacturingPharmaceutical
Responsibilities
Program ownership: Serve as program owner for oligonucleotide discovery and development programs, driving them from target validation through DC nomination and IND submission
Oligo design and development: Lead the strategy and execution for antisense oligonucleotides and siRNAs, with a particular emphasis on conjugated oligos (e.g., GalNAc, peptide, antibody, or other ligand-based conjugates)
Assay development: Establish and oversee cellular and biochemical assays to evaluate oligo potency, specificity, uptake, trafficking, and mechanism of action. Ensure assay platforms are robust, scalable, and reproducible
Conjugation biology: Partner closely with chemistry and delivery teams to design and optimize conjugated oligos; directly contribute to design hypotheses and screen conjugates in relevant cellular and in vivo models
Development candidate nomination: Drive scientific packages and cross-functional decision-making to select and nominate oligo development candidates for IND-enabling studies
IND-enabling leadership: Guide IND-enabling biology and translational strategy, integrating preclinical data, biomarkers, and mechanistic insights into regulatory filings
Translational strategy: Build and apply translational models that connect preclinical findings with human biology. Develop and integrate biomarker strategies to guide dose selection, patient stratification, and early clinical readouts
Cross-functional leadership: Lead and inspire cross-functional program teams, ensuring alignment across biology, chemistry, DMPK, CMC, toxicology, and clinical groups to deliver on program objectives
External collaboration: Evaluate and manage CROs and academic partnerships to accelerate program timelines while ensuring scientific rigor and data quality
Regulatory support: Provide biological and translational expertise to regulatory documents, including IND packages, Investigator’s Brochures, and briefing books
Qualification
Required
Ph.D. in molecular biology, pharmacology, or related field, or equivalent advanced degree
12+ years of experience in oligonucleotide drug discovery and development, with at least 5 years in a leadership role
Strong track record of nominating oligonucleotide development candidates and driving programs into IND
Expertise in assay development, in vitro and in vivo pharmacology, and translational/biomarker strategy
Demonstrated ability to lead cross-functional programs through IND-enabling studies
Preferred
Regulatory-facing experience strongly preferred
Experience spanning both antisense and siRNA modalities
Exposure to multiple conjugation approaches (GalNAc, peptides, antibodies, lipids)
Direct experience building translational packages and biomarker plans for early-phase clinical development
Proven ability to scale teams and capabilities in a fast-paced biotech environment
Benefits
Robust and market-competitive compensation & benefits package (Base, Performance Bonus, Equity, health, welfare & retirement programs)
Flexible PTO
Rapid career advancement for strong performers
Potential ability to work on multiple GondolaBio Pharma programs across multiple therapeutic areas over time
Partnerships with leading institutions
Commitment to Diversity, Equity & Inclusion
Company
GondolaBio
GondolaBio researches, develops and manufactures pharmaceutical products. It is a sub-organization of BridgeBio.
11-50 employees
Funding
Current Stage
Early StageTotal Funding
$300M2024-08-16Series Unknown· $300M
Leadership Team
J
James Li
President
Recent News
Company data provided by crunchbase